Health-Economic Analysis of Digestive Stents in France Based on the French Social Insurance Healthcare Database
Author(s)
de Launay J1, Saidani N2, Mison F3, Bertucat A4, Lamarsalle L5, Panes A5, Spoljar T6
1Becton, Dickinson and Company, Paris, Île-de-France, France, 2Boston Scientific, Voisins le Bretonneux, Yvelines, France, 3COOK France, Paris, Île-de-France, France, 4Duomed France Endoscopie, Bagnolet, Île-de-France, France, 5HEVA, Lyon, Rhône, France, 6Heva, USA
Presentation Documents
OBJECTIVES: Describe cost of stays and implantation of digestive stents (DS) and simulate the impact of potential inclusion of DS in DRGs.
METHODS: An observational retrospective study was conducted using the French Hospital Discharge System (Programme de Médicalisation des Systèmes d’Information, PMSI). The study population consisted of patients who received a DS implantation in France in 2019 and 2020. The costs of stays were described for public and private hospitals. The potential inclusion of the costs of these implants into DRG tariffs was also simulated.
RESULTS: The frequency of stents used in the main DRGs was <1% for digestive non-biliary localizations in public and private hospitals. DS were used in 2,314 stays identified in 2 main DRGs (1,160 and 1,154) in public hospitals among 295,922 and 209,499 total stays respectively. Total cost of these stays with DS were €977,832 and €1,042,174 respectively, for an average DS cost/stay of €3 and €5. Simulation of the inclusion of these stents in DRGs was not conclusive. Biliary localizations were more frequent (9.7% in public hospitals, 17.6% in private hospitals). DS were used in 16,592 stays identified in 2 main DRGs (11,094 and 5,498) in public hospitals among 119,804 and 65,830 total stays respectively. Total cost of these stays with DS were €7,436,929 and €4,624,381 respectively, for an average DS cost/stay of €62 and €70. Simulation of the inclusion of these stents in DRGs resulted in a modest windfall effect with a maximum of €550,000. Results were similar for private hospitals.
CONCLUSIONS: This study highlights that the inclusion of low numbers of digestive stents into a high-use DRG, could result in under-reimbursement under circumstances of stent use. The inclusion in DRGs could potentially reduce the chances of treatment for patients concerned, particularly for biliary localizations that are mostly done by centers of excellence.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
EE129
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Budget Impact Analysis, Public Spending & National Health Expenditures, Reimbursement & Access Policy
Disease
Gastrointestinal Disorders, Medical Devices